<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To demonstrate the association between <z:chebi fb="1" ids="50694">minocycline</z:chebi> treatment and development of the <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A retrospective study was conducted of 12 patients from five neuro-ophthalmic referral centers who developed <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri syndrome</z:e> after being treated with standard doses of <z:chebi fb="1" ids="50694">minocycline</z:chebi> for refractory <z:hpo ids='HP_0001061'>acne</z:hpo> vulgaris </plain></SENT>
<SENT sid="2" pm="."><plain>The main outcome measures included resolution of <z:hpo ids='HP_0002315'>headaches</z:hpo>, transient visual obscurations, <z:hpo ids='HP_0000651'>diplopia</z:hpo>, <z:hpo ids='HP_0001085'>papilledema</z:hpo>, and visual fields static thresholds after withdrawal of <z:chebi fb="1" ids="50694">minocycline</z:chebi> and treatment for <z:hpo ids='HP_0002516'>increased intracranial pressure</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Nine (75%) of the 12 patients developed symptoms of the <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri syndrome</z:e> syndrome within 8 weeks of starting <z:chebi fb="1" ids="50694">minocycline</z:chebi> therapy; six were not <z:mp ids='MP_0001261'>obese</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Two patients developed symptoms only after a year had elapsed because of commencement of treatment with <z:chebi fb="1" ids="50694">minocycline</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>One patient was asymptomatic, and <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri syndrome</z:e> was diagnosed by finding <z:hpo ids='HP_0001085'>papilledema</z:hpo> on routine examination 1 year after <z:chebi fb="1" ids="50694">minocycline</z:chebi> was started </plain></SENT>
<SENT sid="6" pm="."><plain>None of the patients developed recurrences for at least 1 year after the discontinuation of <z:chebi fb="1" ids="50694">minocycline</z:chebi> and treatment for <z:hpo ids='HP_0002516'>increased intracranial pressure</z:hpo>, but three (25%) of the 12 patients had substantial residual visual field loss </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: <z:chebi fb="1" ids="50694">Minocycline</z:chebi> is a cause or precipitating factor in <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri syndrome</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Although most patients have prominent symptoms and are diagnosed promptly, others are asymptomatic and may have optic disk <z:hpo ids='HP_0000969'>edema</z:hpo> for a long period of time before diagnosis </plain></SENT>
<SENT sid="9" pm="."><plain>Withdrawal of <z:chebi fb="1" ids="50694">minocycline</z:chebi> and treatment for <z:hpo ids='HP_0002516'>increased intracranial pressure</z:hpo> lead to resolution of the <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumor cerebri syndrome</z:e>, but visual field loss may persist </plain></SENT>
</text></document>